|
시장보고서
상품코드
2049528
골다공증 치료제 시장 보고서 : 제품 유형별, 투여 경로별, 지역별(2026-2034년)Osteoporosis Drugs Market Report by Product Type, Route of Administration, and Region 2026-2034 |
||||||
세계의 골다공증 치료제 시장 규모는 2025년에 180억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 254억 달러에 달하고, 2026년부터 2034년까지 CAGR 3.82%로 성장할 것으로 예측했습니다.
골다공증은 뼈 조직과 뼈의 강도가 감소하는 질환입니다. X선, 컴퓨터단층촬영(CT), 자기공명영상법(MRI) 등 다양한 검사를 통해 진단합니다. 현재 골다공증 증상 완화를 위해 일반 정제부터 정맥주사까지 다양한 제형의 약물을 사용할 수 있습니다. 이러한 약물은 뼈의 흡수와 형성의 균형을 회복하고, 뼈의 미세한 결함을 복구하고, 골절의 위험을 줄이고, 환자의 전반적인 근력을 향상시키는 데 도움이 됩니다.
좌식 생활, 과도한 음주, 흡연율 증가로 인한 골다공증 유병률 증가는 시장 성장을 촉진하는 주요 요인으로 작용하고 있습니다. 체강 질병, 신장 및 간 질환, 암, 루푸스, 다발성 골수종, 류마티스 관절염을 앓고 있는 사람들의 증가도 시장 성장을 더욱 가속화하고 있습니다. 또한, 골량 감소는 노화와 함께 진행되기 때문에 노년층에서 골다공증 발병 위험이 높아집니다. 그 결과, 고령 인구의 증가는 전 세계 골다공증 치료제 수요에 긍정적인 영향을 미치고 있습니다. 또한, 여러 규제 당국이 새로운 치료제를 개발하고 있으며, 이 또한 시장 성장에 기여하고 있습니다. 예를 들어, 미국 식품의약국(FDA)은 골절 위험이 높거나 다른 골다공증 치료에 내약성이 없는 폐경 후 여성을 위한 새로운 골다공증 치료제를 승인했습니다. 이 외에도 후기 임상시험 단계에 있는 다양한 약물들이 향후 몇 년 동안 시장 성장을 견인할 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 골다공증 치료제 시장
제6장 시장 내역 : 제품 유형별
제7장 시장 내역 : 투여 경로별
제8장 시장 내역 : 지역별
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
KSM 26.06.10The global osteoporosis drugs market size reached USD 18.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 25.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.82% during 2026-2034.
Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.
The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years.
KEY MARKET SEGMENTATION:
Breakup by Product Type:
- Bisphosphonates
- Calcitonin
- Rank Ligand Inhibitor
- Parathyroid Hormone Therapy (PTH)
- Selective Estrogen Receptor Modulators (SERMs)
- Sclerostin Inhibitor
- Others
Breakup by Route of Administration:
- Oral
- Injectable
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.
Key Questions Answered in This Report
1. How big is the global osteoporosis drugs market?
2. What is the expected growth rate of the global osteoporosis drugs market during 2026-2034?
3. What are the key factors driving the global osteoporosis drugs market?
4. What has been the impact of COVID-19 on the global osteoporosis drugs market?
5. What is the breakup of the global osteoporosis drugs market based on the product type?
6. What is the breakup of the global osteoporosis drugs market based on the route of administration?
7. What are the key regions in the global osteoporosis drugs market?
8. Who are the key players/companies in the global osteoporosis drugs market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Osteoporosis Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Bisphosphonates
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Calcitonin
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Rank Ligand Inhibitor
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Parathyroid Hormone Therapy (PTH)
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Selective Estrogen Receptor Modulators (SERMs)
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Sclerostin Inhibitor
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Injectable
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Amgen Inc.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Eli Lilly and Company
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 F. Hoffmann-La Roche AG
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 SWOT Analysis
- 13.3.4 GlaxoSmithKline Plc
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Merck & Co. Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Novartis AG
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Pfizer Inc.
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Radius Health Inc.
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.9 Teva Pharmaceutical Industries Ltd.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.10 UCB S.A.
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financials
- 13.3.10.4 SWOT Analysis
- 13.3.1 Amgen Inc.
